Xtx Topco LTD Biomarin Pharmaceutical Inc Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Xtx Topco LTD holds 6,898 shares of BMRN stock, worth $446,231. This represents 0.04% of its overall portfolio holdings.

Number of Shares

6,898

Previous 5,018 37.47%

Holding current value

$446,231

Previous $413,000 17.19%

% of portfolio

0.04%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $129,757 - $176,419	1,880 Added 37.47%	6,898 $484,000
Q2 2024 Aug 12, 2024	SELL	$74.43 - $92.22 $455,586 - $564,478	-6,121 Reduced 54.95%	5,018 $413,000
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $756,720 - $893,871	9,029 Added 427.91%	11,139 $972,000
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $581,634 - $751,729	-7,631 Reduced 78.34%	2,110 $203,000
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $539,258 - $598,908	-6,339 Reduced 39.42%	9,741 $861,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $1.39 Million - $1.61 Million	16,080 New	16,080 $1.39 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $281,960 - $378,466	3,484 New	3,484 $360,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $268,478 - $326,208	-3,756 Reduced 48.19%	4,038 $335,000
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $354,389 - $442,223	4,771 Added 157.82%	7,794 $601,000
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $216,809 - $276,513	3,023 New	3,023 $267,000
Q2 2021 Aug 12, 2021	SELL	$75.51 - $84.79 $524,567 - $589,036	-6,947 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $519,149 - $630,023	6,947 New	6,947 $525,000

Others Institutions Holding BMRN

# of Institutions

638

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account